Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc.

I'll research this case before drafting the overview.

Good material. Let me get the appellate details, panel, counsel, and IPR linkage.

Let me verify the cross-appeal, IPR linkage, and district court counsel.

Case Overview — Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. Nos. 2016-1284, 2016-1787)

Parties, product, and posture. This is a brand-vs.-generic Hatch‑Waxman case, not an NPE/PAE or university assertion. Plaintiff‑appellee Helsinn Healthcare S.A. is a Swiss specialty pharma company that owns the palonosetron franchise underlying its branded antiemetic Aloxi® (palonosetron hydrochloride injection; NDA 21‑372, approved July 25, 2003), and co‑plaintiff Roche Palo Alto LLC is the Roche/Syntex successor entity from which Helsinn took a 1998 license to palonosetron and the earlier U.S. Patent No. 5,202,333 (the "'333 patent"). Defendants‑appellants Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. are, respectively, the U.S. affiliate and the Israeli parent of the world's largest generic manufacturer. The accused conduct is Teva's submission of ANDA No. 090713 — a consolidated Paragraph IV ANDA covering generic palonosetron HCl IV solution in 0.25 mg/5 mL (CINV indication) and 0.075 mg/1.5 mL (PONV indication) strengths — which Helsinn alleged infringed under 35 U.S.C. § 271(e)(2)(A). The litigation was filed in the **U.S. District Court for the District of New

I'll research this case thoroughly. Let me start with several searches.

I'll search for press coverage of this case from multiple angles.

Good foundation. Now let me verify the specific articles listed in the task.

Now let me verify the remaining listed articles and look for Helsinn-specific coverage.

Press and analysis coverage of Helsinn v. Teva

The Federal Circuit phase (2016–2018). The most granular running account of the appeal is Law360's case page for Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., which carries dated staff summaries of each milestone: a September 30, 2016 preview noting the panel "could decide … the AIA's on-sale bar provision covers only sales to the public"; an October 4, 2016 report that the USPTO argued in Helsinn's favor, "backing patent holder Helsinn Healthcare SA in a dispute that pits the 2011 measure against decades of patent law precedent"; the May 1, 2017 decision itself ("reversing a lower court and invalidating four Helsinn Healthcare SA nausea drug patents"); a May 3, 2017 story in which "attorneys say" the court declined a broad AIA ruling yet signaled the doctrine "may not have lost its teeth"; Helsinn's July 5, 2017 en banc petition arguing the panel "subverts" the AIA's "carefully constructed statutory scheme"; a July 11, 2017 letter from then-Rep. Lamar Smith urging rehearing; and July 19, 2017 coverage of amici warning the ruling "threaten[s] to 'destabilize the entire U.S. patent system.'" Law360 also covered the January 16, 2018 denial of rehearing — framing it as a ruling that "clarified that its decision isn't as extreme as the intellectual property world feared" — and the January 2018 stay fight, including a January 26, 2018 report that the Supreme Court "refused to hold up the ruling" while Helsinn pursued certiorari. The ABA's Business Law Today (Joseph Marinelli, March 2018) went deeper on that clarification, quoting Judge O'Malley's concurrence rejecting "mischaracterizations" in Helsinn's petition and amici and stressing that "[a]ll that our panel opinion held was that the particular agreement at issue triggered the on-sale bar, in part—but not exclusively—because it was made public," while flagging as still open "whether an entirely secret sale, the existence of which is not even public, can trigger an on-sale bar." Practitioner commentary in Law360 (Pranay Pattani and Thomas Kelton, May 30, 2017) made the same point, noting the decision "addresses situations involving public sales of inventions" while "questions about situations involving private or secret sales remain open."

The Supreme Court phase (2019). Post-certiorari coverage is dominated by law-firm client alerts rather than beat reporting. Ropes & Gray (January 24, 2019) reported that on January 22, 2019 the Court held the AIA "did not narrow the scope of the on-sale bar" and that "prior 'secret sales' … may invalidate a patent," presenting the result as running "[i]n Counter to Current USPTO Procedure" — a notable editorial framing, since it asserts a conflict with agency practice rather than merely summarizing the holding. Nixon Peabody (December 2019) highlighted Justice Thomas's statement that altering the settled meaning of "on sale" would be "fairly oblique," and reported that almost a year on, no lower court had resolved whether a sale whose existence is never revealed triggers the bar, surveying Barry v. Medtronic, Quest Integrity v. Cokebusters, and Schlumberger v. BICO. Wiggin characterized the decision as maintaining the "status quo" on "secret commercialization," and the Harvard Journal of Law & Technology digest summarized the unanimous outcome and the amicus battle, adopting the briefing's framing that the ruling "may chill biotechnological innovation." Notably, no outlet in this set reported a damages figure or settlement — consistent with the case being an ANDA § 271(e)(2) action where the practical stakes were Teva's approval and launch timing, not a money judgment; the only dollar figure I encountered ($11 million, the MGI agreement) appears in the Cornell LII case summary drawn from the cert-stage filings, not in press reporting.

The listed later articles are progeny commentary, not coverage of this case. Each of the "recent articles" supplied in the prompt discusses Helsinn as controlling precedent in a successor dispute, and should be read that way. Patently-O (Dennis Crouch, August 12, 2024) covered Celanese v. ITC, where the Federal Circuit reaffirmed that "the on-sale bar continues to block patenting of an otherwise secret process when the patentee makes pre-filing sales of product made using that process"; Barnes & Thornburg noted that the Federal Circuit there treated Helsinn as having already rejected Celanese's textual arguments, including the "otherwise available to the public" theory. Patently-O (Crouch, August 5, 2024) analyzed Sanho v. Kaijet, arguing the § 102(b)(2)/(b)(1) safe harbor requires the invention be "

Sources

• No
• MARCH/APRIL 2019
• January 24, 2019
• PRIOR ART
• Helsinn Healthcare S. A. v. Teva Pharmaceuticals USA: Supreme Court Rules Secret Sales Could Bar Patent Eligibility Under the America Invents Act - Helsinn Healthcare S. A. v. Teva Pharmaceuticals USA: Supreme Court Rules Secret Sales Could Bar Patent Eligibility Under the Am...
• Supreme Court Affirms that Secret Sales Are Still Prior Art, Can Bar Patenting, in Counter to Current USPTO Procedure | Insights | Ropes & Gray LLP - - Home
• INVENTION - INVENTION
• PATENTS - PATENTS
• PRIOR ART - PRIOR ART
• Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc.
• in their public filings
• Page 147 – Business Law Today from ABA

I'll research the counsel of record for Helsinn and Roche Palo Alto in this Federal Circuit appeal and the underlying D.N.J. litigation.

Good — the Federal Circuit opinion lists plaintiff-appellee counsel. Let me verify district court counsel, firm affiliations, and the Roche Palo Alto representation.

Let me verify the Federal Circuit docket appearances, the Roche Palo Alto withdrawal, and Loeb & Loeb's role.

Counsel of Record — Plaintiff(s), Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc.

Scope note. The case metadata identifies the plaintiff as Helsinn Healthcare S.A. The underlying consolidated D.N.J. action (Nos. 3:11-cv-03962-MLC-DEA, 3:11-cv-05579, 3:13-cv-05815) was actually brought by two assignee-plaintiffs — Helsinn Healthcare S.A. and Roche Palo Alto LLC — and both appeared as "Plaintiffs‑Appellees" on the Federal Circuit principal brief. Roche Palo Alto moved to withdraw as a party to the appeal in May 2016 (briefs were already on file under both names), so the operative appellee for the argued appeal was Helsinn. The Federal Circuit consolidated appeal numbers were 2016‑1284 and 2016‑1787.

The names below are drawn from the Federal Circuit opinion's counsel block, the principal appellee brief, and district‑court complaints/docket captions — not inferred.

---

1. Federal Circuit counsel of record for Plaintiffs‑Appellees (Nos. 2016‑1284, 2016‑1787)

The opinion's caption block for Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc., 855 F.3d 1356 (Fed. Cir. May 1, 2017), lists appellee counsel as follows (O'Malley argued):

Source: panel opinion counsel block, 855 F.3d 1356 (Fed. Cir. 2017) (Justia PDF); Principal Brief of Plaintiffs‑Appellees Helsinn Healthcare S.A. & Roche Palo Alto LLC, No. 16‑1284 (Fed. Cir.), docketed 04/25/2016 (Fed. Cir. docket entry 62/63 per CourtListener).

---

2. Co‑plaintiff Roche Palo Alto LLC — separate counsel

Source: D.N.J. complaint signature blocks; IPR2015‑01554 Power of Attorney for Roche Palo Alto LLC (July 24, 2015); Federal Circuit docket (motion to withdraw party Roche Palo Alto LLC, May 2016).

---

3. Additional Helsinn counsel appearing in the underlying district court (not on the appellate signature block)

The D.N.J. complaints and filings identify a broader Helsinn team "Of Counsel" alongside the appellate names:

Source: D.N.J. complaints (e.g., No. 3:14-cv-04274 (MLC)(DEA)) signature blocks listing "Of Counsel: Joseph M. O'Malley, Jr., Bruce M. Wexler, Eric W. Dittmann, David M. Conca, Gary Ji, Angela C. Ni … PAUL HASTINGS LLP."

---

Caveats and sourcing flags

• No in‑house counsel appeared of record in the appellate filings I could locate; Helsinn's appellate appearances were all outside counsel (Paul Hastings) with Saul Ewing as local counsel.
• The Federal Circuit docket's specific "Entry of Appearance" docket‑entry numbers (filed Dec. 2015 onward) were not individually retrieved; I have not fabricated any. The firm/attorney attributions above come from the court's own opinion caption block and the filed briefs, which are the most reliable sources.
• Stephen Blake Kinnaird's and Anand Bipin Patel's firm affiliations are stated as of the 2016–17 appeal, per the opinion. If you need their current firms, that should be re‑verified — I did not confirm a post‑2017 move from a primary source.
• The case metadata lists only Helsinn Healthcare S.A. as plaintiff; the record shows Roche Palo Alto LLC was a co‑plaintiff below who withdrew from the appeal in May 2016. This is a refinement, not a contradiction, of the metadata.
• Teva's side (for contrast, not requested) was Winston & Strawn LLP (George C. Lombardi, Chicago, argued) with Lite DePalma Greenberg and Patunas Tarantino as local counsel.

I'll research the counsel of record for the Teva defendants across the Federal Circuit appeal and the underlying D.N.J. litigation.

I have the Federal Circuit team. Now let me dig into the docket entries and the district court/local counsel.

Let me pin down the district court appearances, pro hac vice admissions, and the Supreme Court counsel for Teva.

Counsel of Record for Teva (Defendants-Appellants / Respondents)

Scope note: "Defendant" here is the Teva side in both the Federal Circuit appeal (Nos. 2016‑1284 & 2016‑1787) and the underlying consolidated D.N.J. actions (3:11‑cv‑03962‑MLC‑DEA, 3:11‑cv‑05579‑MLC‑DEA, 3:13‑cv‑05815‑MLC‑DEA), plus the later Supreme Court merits phase (No. 17‑1229). The Teva defendants are Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. The single constant across all phases is Winston & Strawn LLP, with New Jersey local counsel.

---

1. Federal Circuit — Nos. 2016‑1284 / 2016‑1787 (lead appellate counsel)

The Federal Circuit opinion's counsel block states only: "GEORGE C. LOMBARDI, Winston & Strawn LLP, Chicago, IL, argued for defendants‑appellants. Also represented by TYLER JOHANNES, JULIA MANO JOHNSON; STEFFEN NATHANAEL JOHNSON, ANDREW CURTIS NICHOLS, JOVIAL WONG, Washington, DC; KARL LEONARD, The Exoneration Project, Chicago, IL." (opinion, 855 F.3d 1356)

The Certificate of Interest on Teva's corrected opening brief also identifies the full set of Winston & Strawn personnel involved: "George Lombardi, Steffen Johnson, Lynn MacDonald Ulrich, Jovial Wong, Julia Johnson, Andrew Nichols, Lindsay Beyer, Brandon Barker, Karl Leonard, Tyler Johannes, David Luger," plus local counsel "Lite DePalma Greenberg, LLC and Patunas Tarantino LLC (Michael Patunas, Mayra Tarantino)." (Teva corrected brief, Doc. 39)

---

2. District of New Jersey — consolidated actions (trial counsel)

National/lead trial counsel — Winston & Strawn LLP, 35 W. Wacker Dr., Chicago:

• George C. Lombardi
• Lynn MacDonald Ulrich
• Julia M. Johnson
• Brendan F. Barker
• Karl A. Leonard

These five signed the Teva notice(s) of appeal as "Attorneys for Defendants Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd." (notice of appeal, D.N.J.). George C. Lombardi is listed on the D.N.J. briefs as "Of Counsel" alongside the local firm. (Dkt. 124)

Local counsel (New Jersey):

• Michael E. Patunas — lead local counsel / signatory on D.N.J. filings | Lite DePalma Greenberg, LLC (Two Gateway Center / 570 Broad St., Suite 1201, Newark, NJ) — later Patunas Tarantino LLC | Certified as member of the D.N.J. bar and accepted service, pleadings, and court appearances for Teva.
• Mayra V. Tarantino — local counsel | same firms, Newark, NJ | Co‑signed the notice of appeal and numerous D.N.J. filings on behalf of Teva.

The two firms appear on the trial‑court letterhead as "LITE DEPALMA GREENBERG, LLC / Michael E. Patunas / Mayra V. Tarantino … Attorneys for Defendants Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd." (Dkt. 176). One docket entry notes "[n]otice of withdrawal of appearance of counsel … MAYRA VELEZ TARANTINO," confirming she appeared and later withdrew in the D.N.J. action. Flag: the record shows the local firm transitioned from Lite DePalma Greenberg, LLC to Patunas Tarantino LLC over the life of the case.

---

3. Supreme Court — No. 17‑1229 (cert stage)

Teva's Brief in Opposition to Certiorari (filed May 11, 2018) was signed by Winston & Strawn:

• Steffen N. Johnson — Counsel of Record, Winston & Strawn LLP, Washington, DC
• George C. Lombardi, Julia M. Johnson, Tyler G. Johannes — Winston & Strawn LLP, Chicago
• Andrew C. Nichols, Jovial Wong, Christopher E. Mills — Winston & Strawn LLP, Washington, DC

(Teva Brief in Opposition, supremecourt.gov). The service certificate on Helsinn's petition was addressed to George C. Lombardi at Winston & Strawn, Chicago — confirming he remained Teva's principal contact of record through the cert phase. (Certificate of Service, supremecourt.gov)

Not verified: I was not able to confirm from a primary source the identity of Teva's merits‑stage oral advocate at the Supreme Court (Dec. 4, 2018 argument); my searches captured the Winston & Strawn cert‑stage team but not a merits brief cover page. I am therefore not naming a SCOTUS merits counsel — that would require checking the merits brief/argument transcript on supremecourt.gov.

---

Caveats and gaps

• No in‑house Teva counsel was identified in the appellate opinion, briefs, or the docket excerpts I reviewed. If Teva legal‑department attorneys participated, they are not of record in these filings.
• No sealed appearances surfaced; every appearance I found is on the public record (opinion counsel block, brief certificates of interest, notice of appeal, D.N.J. signature blocks).
• Role labels: The Federal Circuit opinion and briefs do not formally designate "lead" vs. "of counsel"; the designations above (lead/argued vs. supporting) are drawn from who argued (Lombardi), who signed as counsel of record (Steffen Johnson), and the brief caption's grouping of attorneys.
• Do not attribute attorneys from Teva's other D.N.J. matters to this case. For example, Devora W. Allon and Lindsey Oken were admitted pro hac vice for Teva in the In re Lamictal antitrust litigation — a different case in which Patunas also served as local counsel — and I found no evidence they appeared in Helsinn.

Key sources

• Federal Circuit opinion, Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017) — FindLaw
• Teva Corrected Brief for Defendants‑Appellants, Fed. Cir. No. 16‑1284, Doc. 39 (Mar. 8, 2016) — Patently‑O PDF
• D.N.J. notice of appeal and brief signature blocks — RPX Insight doc
• Supreme Court Brief in Opposition, No. 17‑1229 (May 11, 2018) — supremecourt.gov
• CourtListener docket, Fed. Cir. 16‑1284 — courtlistener.com/docket/4493898 (entries on entries of appearance and the motion to withdraw Karl Leonard)
• CourtListener docket, D.N.J. 3:11‑cv‑03962 — courtlistener.com/docket/4310416

Cross‑reference flag: This is consistent with — and extends — the "In the news" section's reference to Winston & Strawn and George Lombardi. It also confirms the earlier Case Overview's characterization of the appeal as Teva‑side appellate work by Winston & Strawn; no contradictions with the case metadata were found.